Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA known ✓ | P35790 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 4/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.44 |
| ▸ | INSR | P06213 | 4/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8813009 | 1.00 | MEN1 (0.47) | MEN1KMT2ANPC1ATMKDM4A | |
| Bromide SCHEMBL8562510 | 1.00 | MEN1 (0.47) | MEN1KMT2ANPC1ATMKDM4A | |
| SCHEMBL12215003 | 0.98 | MEN1 (0.49) | MEN1KMT2ANPC1ATMKDM4A | |
| SCHEMBL8746783 | 0.98 | MEN1 (0.49) | MEN1KMT2ANPC1ATMKDM4A | |
| SCHEMBL14429919 | 0.98 | MEN1 (0.49) | MEN1KMT2ANPC1ATMKDM4A | |
| Iodide SCHEMBL8670273 | 0.97 | MEN1 (0.51) | MEN1KMT2ANPC1ATMKDM4A | |
| SCHEMBL11949196 | 0.92 | TERT (0.46) | MEN1KMT2ANPC1ATMKDM4A | |
| SCHEMBL11949225 | 0.90 | MEN1 (0.44) | MEN1KMT2ANPC1ATMKDM4A | |
| SCHEMBL11949221 | 0.86 | MEN1 (0.39) | MEN1KMT2ANPC1ATMKDM4A | |
| Bromide SCHEMBL9065129 | 0.85 | MEN1 (0.50) | MEN1KMT2ANPC1ATMKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116908158-A | Drug mitochondrial toxicity detection method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-10-20 | — | — | CN | claimed |
| EP-2964790-B1 | SIMPLIFIED NUCLEI ANALYSIS PLATFORM AND BIOMARKER MATRIX THAT SUPPORTS GENOTOXIC MODE OF ACTION DETERMINATIONS | LITRON LABORATORIES LTD (US) | 2023-06-07 | — | — | EP | claimed |
| US-12630719-B2 | Fluorescent acridinium salts, synthesis thereof and use for detection of cardiolipin | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2026-05-19 | — | — | US | disclosed |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260069610-A1 | INHIBITION OF EFFEROCYTOSIS AS A TREATMENT TO PREVENT BONE LOSS AND INCREASE BONE DENSITY AND STRENGTH | UNIVERSITY OF ROCHESTER (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260000789-A1 | BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4634212-A1 | INSULIN TREATMENT TO IMPROVE T CELL ENGINEERING | GENENTECH, INC. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250302957-A1 | INSULIN TREATMENT TO IMPROVE T CELL ENGINEERING | GENENTECH INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250282819-A1 | MITOCHONDRIA-SPECIFIC PEPTIDE THAT CAN BE INTRACELLULARLY DELIVERED AT NANOMOLAR CONCENTRATION, AND USE THEREOF | CAMP THERAPEUTICS INC. (KR) | 2025-09-11 | — | — | US | disclosed |
| US-20250276996-A1 | CATIONICALLY-ENFRAMED HIGH DENSITY AROMATIC PEPTIDES | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2025-09-04 | — | — | US | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| WO-2008002745-A2 | METHOD FOR A FULLY AUTOMATED MONOCLONAL ANTIBODY-BASED EXTENDED DIFFERENTIAL | BECKMAN COULTER, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1747460-A2 | METHOD FOR A FULLY AUTOMATED MONOCLONAL ANTIBODY-BASED EXTENDED DIFFERENTIAL | Beckman Coulter, Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060269970-A1 | Method for a fully automated monoclonal antibody-based extended differential | BECKMAN COULTER, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1604039-A2 | DYE COMPOSITIONS WHICH PROVIDE ENHANCED DIFFERENTIAL FLUORESCENCE AND LIGHT SCATTER CHARACTERISTICS | Beckman Coulter, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005114191-A2 | METHOD FOR A FULLY AUTOMATED MONOCLONAL ANTIBODY-BASED EXTENDED DIFFERENTIAL | BECKMAN COULTER, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050260766-A1 | Method for a fully automated monoclonal antibody-based extended differential | BECKMAN COULTER, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-6955872-B2 | Dye compositions which provide enhanced differential fluorescence and light scatter characteristics | COULTER INTERNATIONAL CORP. (US) | 2005-10-18 | — | — | US | disclosed |
| WO-2004085989-A2 | DYE COMPOSITIONS WHICH PROVIDE ENHANCED DIFFERENTIAL FLUORESCENCE AND LIGHT SCATTER CHARACTERISTICS | BECKMAN COULTER, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040185447-A1 | Dye compositions which provide enhanced differential fluorescence and light scatter characteristics | COULTER INTERNATIONAL CORP. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630719-B2 | Fluorescent acridinium salts, synthesis thereof and use for detection of cardiolipin | TIMM10, UQCRC1, TMEM70 | CHKA 675/4885MEN1 3803/4885KMT2A 4744/4885 |
| US-20260000789-A1 | BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION | BAG3, BAG2, BCL3 | CHKA 2928/4885MEN1 4544/4885KMT2A 3814/4885 |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | SHMT2, NLN, TFAM | CHKA 2836/4885MEN1 2463/4885KMT2A 2605/4885 |
| US-20260069610-A1 | INHIBITION OF EFFEROCYTOSIS AS A TREATMENT TO PREVENT BONE LOSS AND INCREASE BONE DENSITY AND STRENGTH | SOST, BST2, CALCR | CHKA 3010/4885MEN1 1963/4885KMT2A 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.